Rate My Professor Jennifer Hines

The lab has produced impactful discoveries, including a new class of medicinal compounds that bind RNA and disrupt its function, published in 2023. In 2021, her team detailed how RNA sequence and ligands alter the SARS-CoV-2 stem loop II motif conformation, identifying a potential antiviral target. Key publications encompass Aldhumani et al., RNA sequence and ligand binding alter conformational profile of SARS-CoV-2 stem loop II motif, Biochemical and Biophysical Research Communications (2021); Shriwas et al., A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism, Cancer & Metabolism (2021); Armstrong et al., RNA Drug discovery: Conformational restriction enhances specific modulation of the T-Box riboswitch function, Bioorganic & Medicinal Chemistry (2020); Ghazanfari et al., A novel GSK-3 inhibitor binds to GSK-3β via a reversible, time and Cys-199-dependent mechanism, Bioorganic & Medicinal Chemistry (2021); Liu et al., Identification of spermidine binding site in T-box riboswitch antiterminator RNA, Chemical Biology & Drug Design (2016); and numerous studies on T-box RNA stability, oxazolidinone and triazole ligands (2008-2015). Hines received a Baker Fund Award of $12,000 in 2017 and an NIH grant of $430,000 in 2019 with Stephen Bergmeier for RNA-targeted antibacterial agents.